Crinetics' acromegaly drug hits primary PhII endpoint, but investors can't make up their minds

Max Gelman

Senior Editor

A little more than two years after first going public, Crinetics Pharmaceuticals is nearing the Phase III trial for its lead program. That candidate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Crinetics' acromegaly drug hits primary PhII endpoint, but investors can't make up their minds

Max Gelman

Senior Editor

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

Sofinnova outlines $550M fund after IPOs and M&A deals

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

FDA approves subcutaneous version of Bristol Myers' Opdivo

WuXi AppTec will sell cell and gene therapy business to private equity firm

Cri­net­ic­s' acromegaly drug hits pri­ma­ry PhII end­point, but in­vestors can't make up their minds

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Crinetics' acromegaly drug hits primary PhII endpoint, but investors can't make up their minds

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

Sofinnova outlines $550M fund after IPOs and M&A deals

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

FDA approves subcutaneous version of Bristol Myers' Opdivo

WuXi AppTec will sell cell and gene therapy business to private equity firm